ライフサイエンスコーパス: esophagogastric junction

1 the work-up for patients with tumors of the esophagogastric junction.

2 tion of adenocarcinomas of the esophagus and esophagogastric junction.

3 for adenocarcinoma of the esophagus and the esophagogastric junction.

4 ip of the nasogastric tube was lodged at the esophagogastric junction.

5 adenocarcinomas arising in the esophagus and esophagogastric junction, 56 Barrett adenocarcinomas, an

6 nitial laparotomy, followed by harvesting of esophagogastric junction 60 days later.

7 with esophageal adenocarcinoma (EAC) and/or esophagogastric junction adenocarcinoma after local ther

8 The stage of esophageal or esophagogastric junction adenocarcinoma after neoadjuvan

9 ize therapy for patients with esophageal and esophagogastric junction adenocarcinoma was effective, i

10 zed consecutive resections for esophageal or esophagogastric junction adenocarcinomas performed at tw

11 management of most resectable esophageal and esophagogastric junction adenocarcinomas.

12 nts with adenocarcinoma of the esophagus and esophagogastric junction (AEG) is poor.

13 CC) of the esophagus, adenocarcinomas of the esophagogastric junction (AEG), or gastric cancer (GC).

14 ; 66 patients (75%) had EGA localized in the esophagogastric junction and 22 in the stomach (25%).

15 3-85.15 years) with biopsy-proved cancer (28 esophagogastric junction and 71 gastric cancers) were ex

16 hronic opioid use with motility disorders of esophagogastric junction and esophageal body peristalsis

17 ders, injection of inert substances into the esophagogastric junction, and electrical stimulation of

18 ectal cancer (CRC), gastric cancer (GC), and esophagogastric junction cancer (EGJC)-is essential for

19 e found in 10-26% of gastric cancer (GC) and esophagogastric junction cancer (EGJC).

20 the treatment of patients with esophageal or esophagogastric-junction cancer is not well established.

21 ients with potentially curable esophageal or esophagogastric-junction cancer.

22 tients undergoing surgery for esophageal and esophagogastric junction cancers across 20 centers (NCT0

23 thy individuals and patients with gastric or esophagogastric junction cancers with sensitivity and sp

24 of HER2 status in tumor tissue in gastric or esophagogastric junction cancers.

25 is capable of selectively analyzing discrete esophagogastric junction contributors (lower esophageal

26 data for adenocarcinoma of the esophagus and esophagogastric junction demonstrate that lymphadenectom

27 .0) versus sham on esophageal physiology and esophagogastric junction (EGJ) anatomy.

28 In some patients, reflux at esophagogastric junction (EGJ) can be seen on the impeda

29 Adenocarcinoma of the esophagus and esophagogastric junction (EGJ) is increasing, the earlie

30 Flow across the esophagogastric junction (EGJ) is strongly related to op

31 Distensibility of the esophagogastric junction (EGJ) largely determines esopha

32 etailed analysis of the mechanics leading to esophagogastric junction (EGJ) opening during transient

33 TBE accuracy for predicting achalasia/FLIP+ esophagogastric junction (EGJ) outflow obstruction, as d

34 pet (270 degrees wrap) fundoplication on the esophagogastric junction (EGJ) pressure in response to d

35 ip between obesity and the morphology of the esophagogastric junction (EGJ) pressure segment using hi

36 f achalasia hinges on demonstrating impaired esophagogastric junction (EGJ) relaxation and aperistals

37 Obstruction at the esophagogastric junction (EGJ) results in esophageal dil

38 ximal stomach above the meal adjacent to the esophagogastric junction (EGJ), referred to as the 'acid

39 tus) provide the sphincter mechanisms at the esophagogastric junction (EGJ).

40 RNA-sequencing analyses linked CM from esophagogastric junction fat of obese patient-induced HI

41 CM from esophagogastric junction fat of obese patients caused di

42 CM from esophagogastric junction fat of obese patients induced r

43 ssion in adenocarcinomas of the esophagus or esophagogastric junction, few studies have assessed the

44 in short segments of columnar mucosa at the esophagogastric junction has clinical importance but can

45 leted nCRT for carcinoma of the esophagus or esophagogastric junction, is not of major importance wit

46 carcinoma of the esophagus (n = 19), cardia (esophagogastric junction, n = 12), or subcardia (n = 6).

47 g FLIP panometry protocol, interpretation of esophagogastric junction opening and contractile respons

48 (FLIP) panometry provides assessment of the esophagogastric junction opening and esophageal body con

49 BEST PRACTICE ADVICE 4: Normal esophagogastric junction opening on FLIP has a high nega

50 e findings supportive of achalasia, abnormal esophagogastric junction opening on FLIP should prompt f

51 th resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either p

52 re of esophageal emptying disorders, such as esophagogastric junction outflow obstruction and achalas

53 , and the development of diagnoses including esophagogastric junction outflow obstruction and hyperco

54 70.7% respectively; p < 0.001), particularly esophagogastric junction outflow obstruction disorders.

55 h negative predictive value for disorders of esophagogastric junction outflow obstruction on high-res

56 supports the diagnosis of a disorder of EGJ [esophagogastric junction] outflow" (median response 8.5;

57 ents with adenocarcinoma of the esophagus or esophagogastric junction received neoadjuvant therapy.

58 Reduction or normalization of the esophagogastric junction relaxation pressure achieved by

59 and specialized populations of cells at the esophagogastric junction (residual embryonic cells and t

60 pic specialized intestinal metaplasia of the esophagogastric junction (SIM-EGJ).

61 epends on alleviating the obstruction at the esophagogastric junction, the postintervention contracti

62 that the disease process progresses from the esophagogastric junction to the esophageal body.

63 rapy for adenocarcinoma of the esophagus and esophagogastric junction using Worldwide Esophageal Canc

64 Capillary content of the esophagogastric junction was quantified using IHC for va